Valion Bio Q2 Loss Widens to $7.1M; Cash Drops to $2.1M, Going Concern Doubt Reiterated
VBIO is trading near its 52-week low of $0.159 (13% above the low) on elevated volume (29× avg).
Summary
Valion Bio reported a $7.1M Q2 net loss, cash down to $2.1M, and reiterated going concern doubt. Subsequent preferred conversions added ~17M shares, and Nasdaq delisting risk remains.
Key Events · Earnings and Guidance · VBIO
-
Q2 Net Loss Widens
Net loss of $7.1M for Q2 2026, up from $1.9M in Q2 2025, driven by higher R&D and SG&A from the CDMO acquisition.
-
Cash Position Deteriorates
Cash and cash equivalents fell to $2.1M as of June 30, 2026, from $12.6M at year-end 2025, with operating cash burn of $10.3M in H1 2026.
-
Going Concern Doubt Reiterated
Management states substantial doubt about the company's ability to continue as a going concern within one year, citing insufficient cash to meet anticipated needs.
-
Nasdaq Delisting Risk
Company remains non-compliant with Nasdaq's $1.00 minimum bid price rule; deadline to regain compliance is September 15, 2026, with a reverse split vote scheduled for August 14, 2026.
Analysis · VBIO · Life Sciences
Valion Bio's Q2 2026 results show a sharply widening loss and a cash position that has fallen to $2.1 million from $12.6 million at year-end. The company reiterates substantial doubt about its ability to continue as a going concern, and it remains out of compliance with Nasdaq's minimum bid price rule with a September 15, 2026 deadline. Subsequent to quarter-end, preferred stock conversions added nearly 17 million common shares, pushing the outstanding count to 22.19 million — a massive dilution event. The filing also discloses a material weakness in internal controls. This is a critical update for investors.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $791.2K. The 52-week trading range was $0.16 to $5.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.